Chen Kebiao, Qin Li, Lu Xin, Xia Tao, Gu Qing
Kebiao Chen, Department of Cardiovascular Surgery, Taian Central Hospital, Shandong, 271000, China.
Li Qin, Department of Cardiovascular Surgery, Taian Central Hospital, Shandong, 271000, China.
Pak J Med Sci. 2019 Jul-Aug;35(4):918-922. doi: 10.12669/pjms.35.4.1298.
To explore the efficacy of amiodarone in the treatment of atrial fibrillation for patients with rheumatic heart disease after valve replacement.
Eighty-six patients with rheumatic heart disease who were hospitalized between June 2016 and June 2017 and developed atrial fibrillation after valvular heart valve replacement were randomly divided into a control group and an observation group, 42 cases in each group. The control group was treated with routine medical treatment, while the observation group was given amiodarone on the basis of routine treatment. The cardiac function of the two groups were observed and recorded. Postoperative atrial fibrillation conversion rate, sinus rhythm maintenance rate, intensive care unit (ICU) monitoring time and hospital stay were compared between the two groups.
Compared with the control group, the improvement of cardiac function indexes of the observation group was better, and the difference was statistically significant (P<0.05). The atrial fibrillation conversion rate and the maintenance rate of sinus rhythm of the observation group were 76.2% and 47.6% respectively, which were significantly higher than 57.1% and 33.3% of the control group; the differences had statistical significance (P<0.05). The ICU monitoring time and hospitalization time of the patients in the observation group were (1.69±0.91) d and (10.24±1.11) d respectively, which were significantly shorter than (2.83±0.95) d and (14.07±1.17) d in the control group (P<0.05); the differences were statistically significant (P<0.05).
Amiodarone can effectively treat valve replacement associated atrial fibrillation of patients with rheumatic heart disease. It can significantly improve the heart function, prevent the recurrence of atrial fibrillation, maintain sinus rhythm after operation, and shorten the time of ICU monitoring and hospitalization.
探讨胺碘酮对风湿性心脏病瓣膜置换术后患者房颤的治疗效果。
选取2016年6月至2017年6月住院的86例风湿性心脏病患者，在心脏瓣膜置换术后发生房颤，随机分为对照组和观察组，每组42例。对照组采用常规药物治疗，观察组在常规治疗基础上加用胺碘酮。观察并记录两组患者的心功能。比较两组患者术后房颤转复率、窦性心律维持率、重症监护病房（ICU）监测时间及住院时间。
与对照组比较，观察组心功能指标改善更明显，差异有统计学意义（P<0.05）。观察组房颤转复率和窦性心律维持率分别为76.2%和47.6%，明显高于对照组的57.1%和33.3%；差异有统计学意义（P<0.05）。观察组患者的ICU监测时间和住院时间分别为（1.69±0.91）d和（10.24±1.11）d，明显短于对照组的（2.83±0.95）d和（14.07±1.17）d（P<0.05）；差异有统计学意义（P<0.05）。
胺碘酮可有效治疗风湿性心脏病患者瓣膜置换术后并发的房颤。可显著改善心功能，预防房颤复发，维持术后窦性心律，缩短ICU监测时间及住院时间。
